Principal Investigator Allan Myerson
The Myerson Group in cooperation with the Novartis Center is exploring the use of various types of continuous crystallization for pharmaceutical intermediates and final crystallization of active pharmaceutical ingredients (API’s). Issues related to purity, polymorphism, crystal size distribution, crystal shape, scaleup and recycle are being studied.